Aktuellt
SENASTE
Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events in the company. We mostly reiterate our stance to the company but have made some adjustments based on the TRIAC II results and revised assumptions for the ReTRIACt trial.
LÄS MER
